
HTGF News
Stay up to date
Our press pages provide up-to-date information on important developments at the High-Tech Gründerfonds and in the HTGF family. This also includes news from our portfolio companies.
We are the media’s go-to contact for all matters relating to start-ups, venture capital and, of course, our portfolio companies. Please get in touch with us.
Press
InfectoPharm invests in AudioCure to advance innovative hearing loss therapy
Drug candidate AC102 in the clinical phase
Heppenheim/Berlin, 13 February 2025 – There is currently no drug approved worldwide for the treatment of sudden hearing loss. However, preclinical and clinical phase-1-studies with the innovative drug candidate AC102 have been promising. AudioCure Pharma, a Berlin-based start-up supported by investors, is driving forward research and development. Now, InfectoPharm, a successful medium-sized company, is joining as a new and essential competence
Press
Modular. Data-driven. Connected. Avelios Medical secures €30 million from Sequoia Capital for its next-generation hospital information system
The funding round is one of the largest Series A rounds in digital health in recent months.
Avelios Medical offers the HIS of the future: designed around hospital workflows, powered by modular microservices, and based on structured data to enable AI-driven care.
Leading hospitals are successfully using Avelios Medical’s software as the modern alternative in the HIS market.
Munich, February 6, 2025 – Avelios Medical, provider of a modern hospital information system (HIS), h
Press
Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion
Financing led by CARMA FUND and RV Invest with participation of High-Tech Gründerfonds and others
Akribion is pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion
Experienced team with a background in biotechnology and company building led by co-CEO’s Dr. Michael Krohn and Lukas Linnig
Dr. Paul Scholz, the principal inventor of G-dase E technology, joins as Head of Research and Development
Akribion Therapeutics (“Akribion”), the earl
Press
Variolytics Secures Growth Financing Round with Nordic Alpha Partners
Stuttgart, January 30th, 2025 – Variolytics is delighted to announce the successful closure of its growth financing round, a significant milestone in the company’s mission to decarbonize the wastewater sector. The financing round, led by Nordic Alpha Partners (NAP), also includes investments from the European Innovation Council (EIC), High-Tech Gründerfonds (HTGF), and Fraunhofer Technology Transfer Fonds (FTTF).
Founded in 2020 as a spin-off from the Fraunhofer Institute, Variolytic